[{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"35a86a04-d158-4bfb-8750-bfb724605cdd","acronym":"P30CA016672","url":"https://clinicaltrials.gov/study/NCT03383575","created_at":"2021-01-18T16:41:48.451Z","updated_at":"2025-02-25T14:37:54.258Z","phase":"Phase 2","brief_title":"Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome","source_id_and_acronym":"NCT03383575 - P30CA016672","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IDH2 • RUNX1 • ASXL1","pipe":" | ","alterations":" IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation","tags":["TP53 • IDH2 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-10"},{"id":"0586b97f-ca3e-4935-90c4-ce0d935a32d9","acronym":"NCI-2020-05261","url":"https://clinicaltrials.gov/study/NCT04493138","created_at":"2021-01-18T21:35:02.627Z","updated_at":"2024-07-02T16:34:59.952Z","phase":"Phase 1/2","brief_title":"Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations","source_id_and_acronym":"NCT04493138 - NCI-2020-05261","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ASXL1","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation","tags":["TP53 • FLT3 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Vanflyta (quizartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-30"},{"id":"290f9c1c-d70d-4aad-827e-5424eb25383a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03047993","created_at":"2021-01-17T17:15:53.781Z","updated_at":"2024-07-02T16:35:03.817Z","phase":"Phase 1/2","brief_title":"Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome","source_id_and_acronym":"NCT03047993","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IDH1 • IDH2 • RUNX1 • ASXL1","pipe":" | ","alterations":" RUNX1 mutation • ASXL1 mutation • EZH2 mutation","tags":["TP53 • IDH1 • IDH2 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation • ASXL1 mutation • EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • telaglenastat (CB-839)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 11/15/2017","start_date":" 11/15/2017","primary_txt":" Primary completion: 03/16/2023","primary_completion_date":" 03/16/2023","study_txt":" Completion: 03/16/2023","study_completion_date":" 03/16/2023","last_update_posted":"2024-05-14"},{"id":"afaf9f09-288f-48be-befd-287bbb78babe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04734990","created_at":"2021-02-02T15:52:24.117Z","updated_at":"2024-07-02T16:35:04.640Z","phase":"Phase 1/2","brief_title":"Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT04734990","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • NRAS • RUNX1 • ASXL1 • SETBP1","pipe":" | ","alterations":" TP53 mutation • NRAS mutation • ASXL1 mutation","tags":["TP53 • NRAS • RUNX1 • ASXL1 • SETBP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NRAS mutation • ASXL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • seclidemstat (SP2577)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/11/2025","primary_completion_date":" 09/11/2025","study_txt":" Completion: 09/11/2025","study_completion_date":" 09/11/2025","last_update_posted":"2024-05-09"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"e36ce158-5d2c-43a5-8d9f-4bf96a854310","acronym":"ALLO-BAT","url":"https://clinicaltrials.gov/study/NCT04217356","created_at":"2021-01-18T20:31:57.752Z","updated_at":"2024-07-02T16:35:13.310Z","phase":"","brief_title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","source_id_and_acronym":"NCT04217356 - ALLO-BAT","lead_sponsor":"University Health Network, Toronto","biomarkers":" TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR","pipe":" | ","alterations":" TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation","tags":["TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • hydroxyurea"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 08/05/2025","primary_completion_date":" 08/05/2025","study_txt":" Completion: 02/05/2026","study_completion_date":" 02/05/2026","last_update_posted":"2024-03-22"},{"id":"b62639b3-3bfc-4f4f-81ac-2892933d901a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05115630","created_at":"2021-11-10T14:13:02.708Z","updated_at":"2024-07-02T16:35:19.132Z","phase":"Phase 1/2","brief_title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","source_id_and_acronym":"NCT05115630","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type","tags":["TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/08/2022","start_date":" 04/08/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-02-16"},{"id":"0f841029-f2ce-4cb1-849c-75709569b46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03613532","created_at":"2021-03-05T16:52:31.672Z","updated_at":"2024-07-02T16:35:22.047Z","phase":"Phase 1","brief_title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","source_id_and_acronym":"NCT03613532","lead_sponsor":"Jacqueline Garcia, MD","biomarkers":" KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type","tags":["KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-26"},{"id":"bf4d31e7-3a74-43c0-9ba3-0d9c7fa6780e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03531736","created_at":"2021-01-18T17:23:50.599Z","updated_at":"2024-07-02T16:35:27.515Z","phase":"Phase 1","brief_title":"T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia","source_id_and_acronym":"NCT03531736","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • FLT3 mutation • RUNX1 mutation • ASXL1 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • FLT3 mutation • RUNX1 mutation • ASXL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 05/09/2018","start_date":" 05/09/2018","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-11-30"},{"id":"319e00c1-4042-4b5b-bae6-7484ffcf0d6f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02880293","created_at":"2021-01-18T14:08:25.525Z","updated_at":"2024-07-02T16:35:28.538Z","phase":"","brief_title":"Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor","source_id_and_acronym":"NCT02880293","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1 • CRLF2 • IKZF1","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • IKZF1 mutation • MLL mutation","tags":["TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1 • CRLF2 • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • IKZF1 mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 08/23/2016","start_date":" 08/23/2016","primary_txt":" Primary completion: 11/20/2023","primary_completion_date":" 11/20/2023","study_txt":" Completion: 11/20/2023","study_completion_date":" 11/20/2023","last_update_posted":"2023-11-21"},{"id":"a103d7a1-1d6f-430c-8b15-91ec953041ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03932643","created_at":"2021-01-18T19:22:14.463Z","updated_at":"2024-07-02T16:35:29.253Z","phase":"Phase 1","brief_title":"ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant","source_id_and_acronym":"NCT03932643","lead_sponsor":"University of Nebraska","biomarkers":" TP53 • RUNX1 • ASXL1","pipe":" | ","alterations":" TP53 mutation • ASXL1 mutation","tags":["TP53 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ASXL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2023-11-14"},{"id":"1ec7ade3-a1ff-44d4-b7ca-e3d08c57d7b8","acronym":"IM-TMI","url":"https://clinicaltrials.gov/study/NCT04187105","created_at":"2021-01-18T20:24:37.787Z","updated_at":"2024-07-02T16:35:37.511Z","phase":"Phase 2","brief_title":"BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)","source_id_and_acronym":"NCT04187105 - IM-TMI","lead_sponsor":"University of Illinois at Chicago","biomarkers":" RUNX1 • ASXL1 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":" | ","alterations":" RUNX1 mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • Chr t(9;11)","tags":["RUNX1 • ASXL1 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 01/27/2020","start_date":" 01/27/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-09-11"},{"id":"a8d426ea-8842-4fc1-bfee-96024bf6f5ae","acronym":"APVO436","url":"https://clinicaltrials.gov/study/NCT03647800","created_at":"2021-05-26T19:57:54.811Z","updated_at":"2024-07-02T16:36:17.299Z","phase":"Phase 1b","brief_title":"Study of APVO436 in Patients With AML or MDS","source_id_and_acronym":"NCT03647800 - APVO436","lead_sponsor":"Aptevo Research and Development LLC","biomarkers":" FLT3 • RUNX1 • ASXL1 • IL3RA","pipe":" | ","alterations":" ASXL1 mutation • CD123 positive • IL3RA positive","tags":["FLT3 • RUNX1 • ASXL1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASXL1 mutation • CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mipletamig (APVO436)"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 06/15/2023","study_completion_date":" 06/15/2023","last_update_posted":"2022-02-10"},{"id":"544d4614-f791-4bd3-b59b-92ae1a8a0f06","acronym":"","url":"https://clinicaltrials.gov/study/NCT02497404","created_at":"2021-01-18T12:02:35.681Z","updated_at":"2024-07-02T16:36:24.176Z","phase":"Phase 2","brief_title":"Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR","source_id_and_acronym":"NCT02497404","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FLT3 • DNMT3A • RUNX1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • ZRSR2","pipe":" | ","alterations":" DNMT3A mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • U2AF1 mutation","tags":["FLT3 • DNMT3A • RUNX1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNMT3A mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Campath (alemtuzumab) • melphalan • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 02/13/2015","start_date":" 02/13/2015","primary_txt":" Primary completion: 06/17/2020","primary_completion_date":" 06/17/2020","study_txt":" Completion: 06/17/2021","study_completion_date":" 06/17/2021","last_update_posted":"2021-09-22"},{"id":"8e9f015e-2f49-43b1-ac27-09c787f2c5c6","acronym":"AZALENA","url":"https://clinicaltrials.gov/study/NCT02472691","created_at":"2021-01-18T11:54:11.739Z","updated_at":"2025-02-25T14:35:40.382Z","phase":"Phase 2","brief_title":"Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT","source_id_and_acronym":"NCT02472691 - AZALENA","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" FLT3 • ASXL1 • TET2 • WT1","pipe":" | ","alterations":" FLT3 mutation • ASXL1 mutation • TET2 mutation","tags":["FLT3 • ASXL1 • TET2 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • ASXL1 mutation • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 04/23/2020","primary_completion_date":" 04/23/2020","study_txt":" Completion: 04/23/2020","study_completion_date":" 04/23/2020","last_update_posted":"2020-05-28"},{"id":"6e2bc0cd-0b27-4b8b-b4cf-d2d75c0f287a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03365661","created_at":"2021-01-18T16:36:35.414Z","updated_at":"2024-07-02T16:37:05.437Z","phase":"Phase 2","brief_title":"QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML","source_id_and_acronym":"NCT03365661","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" TP53 • FLT3 • KIT • DNMT3A • RUNX1 • ASXL1 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • FLT3 mutation • KIT mutation • DNMT3A mutation • ASXL1 mutation","tags":["TP53 • FLT3 • KIT • DNMT3A • RUNX1 • ASXL1 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • FLT3 mutation • KIT mutation • DNMT3A mutation • ASXL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2018-11-09"}]